|
SAMSUNG EPIS HOLDINGS is a holding company established in 2025 that controls two subsidiaries: Samsung Bioepis and Epix Lab. Samsung Bioepis develops and commercializes biosimilars for autoimmune, oncology, ophthalmology, hematology, and bone diseases, with a portfolio including biosimilars of Remicade, Herceptin, Enbrel, Humira, Avastin, Lucentis, Soliris, Eylea, Stelara, Prolia, and Xgeva. The company sells these products globally through partnerships with pharmaceutical companies and direct sales channels in markets including the United States, Europe, Canada, Australia, Brazil, and Japan. Samsung Bioepis is also developing antibody-drug conjugates (ADCs), including a Nectin-4 ADC in clinical trials and an EGFR-HER3 ADC in preclinical stages, in collaboration with Intocell and Phrontline Biopharma. Epix Lab focuses on developing next-generation biotechnology platforms, including peptide-related technologies, for future new drug candidate development and potential technology licensing. Summarised from the company's own disclosures, fiscal year ended May 2026 |
Industry Biotechnology | Homepage samsungepisholdings.com |
| Sector Healthcare | IR page — | |
|
Tags
biosimilars, antibody-drug conjugates, oncology, autoimmune diseases, ophthalmology, hematology, bone diseases, biotechnology platforms, peptide technologies, Samsung Bioepis, Epix Lab, Remicade, Herceptin, Enbrel, Humira, Avastin, Lucentis, Soliris, Eylea, Stelara, Prolia, Xgeva, Nectin-4 ADC, EGFR-HER3 ADC, Intocell, Phrontline Biopharma
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 8.958T |
| Market cap (USD) | $ 6.593B |
| P/E | 104.86 |
| PEG | — |
| P/BV | 1.47 |
| P/S | 35.59 |
| P/OCF | -86.35 |
| P/FCF | -81.38 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 1.4% |
| ROI | 1.4% |
| ROIC | -0.81% |
| Profit margin | 33.9% |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | — |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | — |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -10.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 |
|---|---|
| Revenue | 251.69B |
| Net profit | 85.313B |
| Free cash flow | -110.078B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2025 |
|---|---|
| Balance sheet detail | |
| Trade receivables (KRW) | 382B |
| Borrowings, current (KRW) | 282B |
| Borrowings, non-current (KRW) | 95B |
| Lease liabilities (KRW) | 1.1B |
| Cash and deposits (KRW) | 131B |
| Intangible assets (KRW) | 5.32T |
| Right-of-use assets (KRW) | 1.66B |
| Net debt (borrowings + leases - cash) (KRW) | 247B |
| Cash flow detail | |
| Operating cash flow (KRW) | -104B |
| Purchases of property, plant and equipment (KRW) | -6.33B |
| Purchases of intangible assets (KRW) | -33.7B |
| Change in receivables (cash effect) (KRW) | -59B |
| Change in inventories (cash effect) (KRW) | -13.7B |
| Change in payables (cash effect) (KRW) | -24.7M |
| Share buybacks (cash effect) (KRW) | -20.2B |
| Interest paid (cash effect) (KRW) | -1.67B |
| Income taxes paid (cash effect) (KRW) | -229M |
| Operating cash flow before change in receivables (KRW) | -44.7B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -144B |
| Income detail | |
| Total comprehensive income (KRW) | 87.8B |
| Comprehensive income to owners (KRW) | 87.8B |
| Provision for credit losses (KRW) | 482M |
| Reported | May 15, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding SAMSUNG EPIS HOLDINGS
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| HELX | 0.37% | 376 | $ 104.357K | Jun 30, 2026 |
| AVXC | 0.07% | 1,054 | $ 276.482K | Nov 16, 2026 |
| RFEM | 0.05% | 151 | $ 39.717K | Jul 31, 2026 |
| DFSE | 0.04% | 839 | $ 216.931K | Nov 12, 2026 |
| DFEM | 0.02% | 5,864 | $ 1.516M | Nov 12, 2026 |
| DFEV | 0.01% | 1,045 | $ 270.194K | Nov 12, 2026 |
| DFAX | 0.01% | 5,382 | $ 1.392M | Nov 12, 2026 |
| AVEM | 0.01% | 11,895 | $ 3.12M | Nov 16, 2026 |
| AVSE | 0.01% | 42 | $ 11.017K | Nov 16, 2026 |
| DFAE | 0.01% | 2,914 | $ 753.441K | Nov 12, 2026 |
| DEXC | 0.00% | 49 | $ 12.669K | Nov 12, 2026 |
| DEHP | 0.00% | 70 | $ 18.099K | Nov 12, 2026 |